Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Curious about long-term investing? Learn essential insights that will help you navigate the investment landscape effectively.
27,039 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
As 2025 unfolds, virtra (vtsi) earnings will hinge on how the company scales its training systems, monetizes software...
As an investor, timing updates can boost or trim returns. This guide breaks down whether should taiwan semiconductor ...
Serve Robotics has faced a meaningful pullback, but a closer look at its partnerships, deployment plans, and unit eco...
Interpreting a quarterly earnings transcript can reveal a company’s true momentum. This guide shows how to read Perim...
In early 2026, Tutor Perini faced a mix of growth opportunities and project-level headwinds. This article breaks down...
Institutional moves can reshape a niche tech stock overnight. This article breaks down the recent liquidation by Loun...
A limited hantavirus outbreak has sent waves through biotech stocks, mirroring post-pandemic behavior. This article b...
Rumors around chip supply and product timelines can move markets quickly. This guide shows how AMD typically responds...
A major fund just raised its stake in a leading data-center company. This article breaks down what that move could me...
A major fund reduced its TransAlta stake in Q4, sparking questions about the stock’s trajectory. This article explain...
Nvidia stock investors just received a wave of bullish commentary from analysts as AI demand powers data centers and ...